Imunon (IMNN) Competitors $8.50 +0.21 (+2.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.39 -0.11 (-1.29%) As of 08/1/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. MDCX, CLSD, MRSN, LVTX, KPTI, XLO, AKTX, MAAQ, SNYR, and RANIShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Medicus Pharma (MDCX), Clearside Biomedical (CLSD), Mersana Therapeutics (MRSN), LAVA Therapeutics (LVTX), Karyopharm Therapeutics (KPTI), Xilio Therapeutics (XLO), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Synergy CHC (SNYR), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors Medicus Pharma Clearside Biomedical Mersana Therapeutics LAVA Therapeutics Karyopharm Therapeutics Xilio Therapeutics Akari Therapeutics Mana Capital Acquisition Synergy CHC Rani Therapeutics Medicus Pharma (NASDAQ:MDCX) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Is MDCX or IMNN more profitable? Medicus Pharma's return on equity of -380.03% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A -380.03% -224.22% Imunon N/A -427.98%-175.03% Do institutionals and insiders have more ownership in MDCX or IMNN? 4.5% of Imunon shares are owned by institutional investors. 11.2% of Medicus Pharma shares are owned by insiders. Comparatively, 6.0% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer MDCX or IMNN? In the previous week, Imunon had 5 more articles in the media than Medicus Pharma. MarketBeat recorded 6 mentions for Imunon and 1 mentions for Medicus Pharma. Medicus Pharma's average media sentiment score of 0.95 beat Imunon's score of -0.04 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer MDCX or IMNN? Medicus Pharma currently has a consensus target price of $23.50, suggesting a potential upside of 814.40%. Imunon has a consensus target price of $232.50, suggesting a potential upside of 2,635.29%. Given Imunon's higher probable upside, analysts clearly believe Imunon is more favorable than Medicus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has better earnings and valuation, MDCX or IMNN? Medicus Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/A-$11.16M-$1.16-2.22ImunonN/AN/A-$18.62M-$20.39-0.42 SummaryMedicus Pharma beats Imunon on 8 of the 13 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.78M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-0.4217.6228.6723.80Price / SalesN/A269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book1.948.508.275.55Net Income-$18.62M-$55.06M$3.24B$259.03M7 Day Performance21.43%-3.98%-3.63%-4.56%1 Month Performance-29.17%9.59%4.40%4.49%1 Year Performance-49.85%6.72%25.97%18.05% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.4452 of 5 stars$8.50+2.5%$232.50+2,635.3%-57.7%$11.78MN/A-0.4230Upcoming EarningsDividend AnnouncementStock SplitMDCXMedicus Pharma2.4465 of 5 stars$2.44-16.7%$23.50+863.1%N/A$39.77MN/A-2.10N/AUpcoming EarningsCLSDClearside Biomedical2.9902 of 5 stars$0.45-10.5%$4.20+843.6%-66.0%$38.64M$1.66M-1.0930Positive NewsGap DownMRSNMersana Therapeutics4.0218 of 5 stars$6.83-11.3%$130.00+1,803.4%-85.3%$38.39M$40.50M-11.58150Stock SplitGap DownLVTXLAVA Therapeutics1.4815 of 5 stars$1.52+6.3%$3.17+108.3%-30.7%$37.62M$11.98M-1.4660High Trading VolumeKPTIKaryopharm Therapeutics3.4144 of 5 stars$4.37+0.5%$37.40+755.8%-71.6%$37.58M$145.24M-0.33380Upcoming EarningsXLOXilio Therapeutics3.212 of 5 stars$0.68-2.1%$4.00+486.5%-31.6%$36.08M$6.34M-0.8170News CoverageAKTXAkari Therapeutics2.6588 of 5 stars$1.14+1.3%$5.00+340.5%-73.1%$36.04MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.39-4.2%N/A+875.0%$35.65MN/A0.001SNYRSynergy CHC3.8562 of 5 stars$3.72-1.8%$10.00+168.8%+3,260.0%$34.85M$34.83M0.0040Trending NewsRANIRani Therapeutics1.7374 of 5 stars$0.55+3.6%$7.33+1,231.2%-80.6%$33.63M$1.03M-0.56110Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies MDCX Competitors CLSD Competitors MRSN Competitors LVTX Competitors KPTI Competitors XLO Competitors AKTX Competitors MAAQ Competitors SNYR Competitors RANI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
